AUROBINDO PHARMA 2018-19 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA 2018-19 Annual Report Analysis
Wed, 6 Nov

AUROBINDO PHARMA has announced its results for the year ended March 2019. Let us have a look at the detailed performance review of the company during FY18-19.

AUROBINDO PHARMA Income Statement Analysis

  • Operating income during the year rose 18.6% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 4.8% YoY during the fiscal. Operating profit margins witnessed a fall and stood at 20.2% in FY19 as against 22.9% in FY18.
  • Depreciation charges increased by 19.7% and finance costs increased by 237.9% YoY, respectively.
  • Other income grew by 52.3% YoY.
  • Net profit for the year declined by 2.4% YoY.
  • Net profit margins during the year declined from 14.6% in FY18 to 12.0% in FY19.

AUROBINDO PHARMA Income Statement 2018-19

No. of Mths Year Ending 12 Mar-18* 12 Mar-19* % Change
Net Sales Rs m 164,998 195,636 18.6%
Other income Rs m 1,020 1,553 52.3%
Total Revenues Rs m 166,018 197,189 18.8%
Gross profit Rs m 37,718 39,519 4.8%
Depreciation Rs m 5,580 6,680 19.7%
Interest Rs m 777 2,626 237.9%
Profit before tax Rs m 32,380 31,767 -1.9%
Tax Rs m 8,183 7,269 -11.2%
Profit after tax Rs m 24,229 23,645 -2.4%
Gross profit margin % 22.9 20.2
Effective tax rate % 25.3 22.9
Net profit margin % 14.6 12.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Listen In: Our Investor Hour Podcast Connects You with the World's Most Successful Investors

AUROBINDO PHARMA Balance Sheet Analysis

  • The company's current liabilities during FY19 stood at Rs 120 billion as compared to Rs 87 billion in FY18, thereby witnessing an increase of 39.0%.
  • Long-term debt down at Rs 2 billion as compared to Rs 5 billion during FY18, a fall of 60.1%.
  • Current assets rose 26% and stood at Rs 154 billion, while fixed assets rose 25% and stood at Rs 104 billion in FY19.
  • Overall, the total assets and liabilities for FY19 stood at Rs 265 billion as against Rs 211 billion during FY18, thereby witnessing a growth of 25%.

AUROBINDO PHARMA Balance Sheet as on March 2019

No. of Mths Year Ending 12 Mar-18* 12 Mar-19* % Change
Networth Rs m 116,804 138,908 18.9
 
Current Liabilities Rs m 86,659 120,429 39.0
Long-term Debt Rs m 4,512 1,800 -60.1
Total Liabilities Rs m 211,052 264,544 25.3
 
Current assets Rs m 121,878 153,645 26.1
Fixed Assets Rs m 83,345 103,909 24.7
Total Assets Rs m 211,052 264,544 25.3
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



AUROBINDO PHARMA Cash Flow Statement Analysis

  • AUROBINDO PHARMA's cash flow from operating activities (CFO) during FY19 stood at Rs 16 billion on a YoY basis.
  • Cash flow from investing activities (CFI) during FY19 stood at Rs -29 billion, an improvement of 49.3% on a YoY basis.
  • Cash flow from financial activities (CFF) during FY19 stood at Rs 19 billion, an improvement of 122% on a YoY basis.
  • Overall, net cash flows for the company during FY19 stood at Rs 7 billion from the Rs 9 billion net cash flows seen during FY18.

AUROBINDO PHARMA Cash Flow Statement 2018-19

Particulars No. of months 12 12 % Change
Year Ending Mar-18 Mar-19
Cash Flow from Operating Activities Rs m 19,545 16,220 -17.0%
Cash Flow from Investing Activities Rs m -19,266 -28,768 -
Cash Flow from Financing Activities Rs m 8,642 19,191 122.1%
Net Cash Flow Rs m 8,919 6,656 -25.4%
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for AUROBINDO PHARMA

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 40.4, an decline from the EPS of Rs 41.4 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 454.5, stands at 10.5 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 2.9 times, while the price to sales ratio stands at 2.0 times.
  • The company's price to cash flow (P/CF) ratio stood at 8.8 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-18* 12 Mar-19*
Sales per share (Unadj.) Rs 281.6 333.9
TTM Earnings per share Rs 41.4 40.4
Diluted earnings per share Rs 41.4 40.4
Price to Cash Flow x 8.9 8.8
TTM P/E ratio x 10.5 10.5
Price / Book Value ratio x 3.3 2.9
Market Cap Rs m 266,282 265,959
Dividends per share (Unadj.) Rs 2.5 2.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for AUROBINDO PHARMA

  • Solvency Ratios
  • Current Ratio: The company's current ratio deteriorated and stood at 1.3x during FY19, from 1.4x during FY18. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 13.1x during FY19, from 42.7x during FY18. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 17.0% during FY19, from 20.7% during FY19. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 23.8% during FY19, from 27.4% during FY18. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 9.9% during FY19, from 11.8% during FY18. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-18* 12 Mar-19*
Current ratio x 1.4 1.3
Debtors’ Days Days 68 64
Interest coverage x 42.7 13.1
Debt to equity ratio x 0.0 0.0
Return on assets % 11.8 9.9
Return on equity % 20.7 17.0
Return on capital employed % 27.4 23.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how AUROBINDO PHARMA has performed over the last 5 years, please visit here.

AUROBINDO PHARMA Share Price Performance

Over the last one year, AUROBINDO PHARMA share price has moved down from Rs 786.2 to Rs 454.5, registering a loss of Rs 331.7 or around 42.2%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,255.0 (up 0.5%). Over the last one year it has moved down from 14,441.9 to 13,255.0, a loss of 1,187 points (down 8.2%).

Overall, the S&P BSE SENSEX is up 15.1% over the year.

(To know more, check out historical annual results for AUROBINDO PHARMA and quarterly results for AUROBINDO PHARMA)

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA 2018-19 Annual Report Analysis". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - TEVA PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS